A plethora of studies have documented that gene expression profiling using DNA microarrays for various types of hematological malignancies provides novel information, which may have diagnostic and prognostic implications. However, to successfully use microarrays for this purpose, the quality and reproducibility of the whole procedure need to be guaranteed. Critical steps of the method are handling, processing and storage of the leukemic sample, purification of tumor cells (or lack thereof), RNA extraction methods, quality control of RNA, labeling techniques, hybridization, washing, scanning, spot filtering, normalization and initial interpretation, and finally the biostatistical analysis. These items have been extensively discussed and evaluated in different multi-center quality rounds within the three networks, that is, I-BFM-SG, the German Competence Network 'Acute and Chronic Leukemias' and the European LeukemiaNet. Based on the exchange of knowledge and experience between the three networks over the last few years, we have formulated guidelines for performing microarray experiments in leukemia. We confine ourselves to leukemias, but many of these requirements also apply to lymphomas or other clinical samples, including solid tumors.

, ,
doi.org/10.1038/sj.leu.2404274, hdl.handle.net/1765/61304
Department of Immunology

Staal, F.J.T, Cario, G, Cazzaniga, G, Haferlach, T, Heuser, M, Hofmann, W.K, … Schlegelberger, B. (2006). Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia, 20(8), 1385–1392. doi:10.1038/sj.leu.2404274